[go: up one dir, main page]

MX2022006940A - Composiciones farmaceuticas. - Google Patents

Composiciones farmaceuticas.

Info

Publication number
MX2022006940A
MX2022006940A MX2022006940A MX2022006940A MX2022006940A MX 2022006940 A MX2022006940 A MX 2022006940A MX 2022006940 A MX2022006940 A MX 2022006940A MX 2022006940 A MX2022006940 A MX 2022006940A MX 2022006940 A MX2022006940 A MX 2022006940A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
relates
treatment
hiv
cabotegravir
Prior art date
Application number
MX2022006940A
Other languages
English (en)
Inventor
Nima Akhavein
Kevin Chu
Emile Velthuisen
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of MX2022006940A publication Critical patent/MX2022006940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a tratamiento del Virus de la Inmunodeficiencia Humana (VIH). En particular, la invención se refiere a una composición farmacéutica que comprende cabotegravir o una sal farmacéuticamente aceptable del mismo, polietilen glicol y poloxámero útil como tratamiento del VIH de acción prolongada.
MX2022006940A 2019-12-09 2020-12-07 Composiciones farmaceuticas. MX2022006940A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945412P 2019-12-09 2019-12-09
US202062982305P 2020-02-27 2020-02-27
PCT/IB2020/061582 WO2021116872A1 (en) 2019-12-09 2020-12-07 Pharmaceutical compositions comprising cabotegravir

Publications (1)

Publication Number Publication Date
MX2022006940A true MX2022006940A (es) 2022-07-11

Family

ID=73834567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006940A MX2022006940A (es) 2019-12-09 2020-12-07 Composiciones farmaceuticas.

Country Status (13)

Country Link
US (1) US20230045509A1 (es)
EP (1) EP4072520B1 (es)
JP (1) JP7703538B2 (es)
KR (1) KR20220112771A (es)
CN (1) CN114786648A (es)
AU (1) AU2020402659A1 (es)
BR (1) BR112022010574A2 (es)
CA (1) CA3164528A1 (es)
IL (1) IL293566A (es)
MX (1) MX2022006940A (es)
TW (1) TW202135815A (es)
UY (1) UY38982A (es)
WO (1) WO2021116872A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
EP4041729B1 (en) * 2019-10-08 2023-09-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2025068743A1 (en) * 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
TW202421168A (zh) * 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
JP2023539344A (ja) 2020-09-01 2023-09-13 ヴィーブ、ヘルスケア、カンパニー カボテグラビルおよびレボノルゲストレルの組合せ
US20250296988A1 (en) * 2020-12-07 2025-09-25 Viiv Healthcare Company Combination therapy
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
WO2025068912A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025128498A1 (en) * 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
PL3372281T3 (pl) 2005-04-28 2021-12-27 Viiv Healthcare Company Policykliczne pochodne karbamoilopirydonu o aktywności inhibitorowej wobec integrazy HIV
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US20170165271A1 (en) * 2014-02-24 2017-06-15 The Board Of Regents Of The University Of Nebraska Compositions and Methods for the Delivery of Therapeutics
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
HUE051719T2 (hu) * 2014-04-11 2021-03-29 Viiv Healthcare Uk No 4 Ltd Triterpenoidok HIV érésgátló aktivitással, amelyek a 3-helyzetben egy halogénalkil-szubsztituenst hordozó nem-aromás gyûrûvel helyettesítettek
KR20170056702A (ko) * 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
RU2745204C2 (ru) * 2016-02-12 2021-03-22 Сипла Лимитед Фармацевтические композиции, содержащие антиретровирусное лекарство и улучшитель фармакокинетики
WO2017223280A2 (en) * 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
EP3478324A1 (en) * 2016-07-01 2019-05-08 GlaxoSmithKline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
UY37710A (es) * 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物
US11505543B2 (en) * 2018-04-11 2022-11-22 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
EP4321164A3 (en) * 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
TWI842721B (zh) * 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
JP7398448B2 (ja) 2018-10-24 2023-12-14 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
CN113382737B (zh) * 2018-11-29 2025-06-03 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3934760A1 (en) 2019-03-06 2022-01-12 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
EP3962603A1 (en) * 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PE20220510A1 (es) * 2019-06-19 2022-04-07 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana
AU2020346907A1 (en) * 2019-09-11 2022-03-24 The Scripps Research Institute Antiviral prodrugs and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
JP7703538B2 (ja) 2025-07-07
IL293566A (en) 2022-08-01
TW202135815A (zh) 2021-10-01
WO2021116872A1 (en) 2021-06-17
AU2020402659A1 (en) 2022-06-02
EP4072520A1 (en) 2022-10-19
KR20220112771A (ko) 2022-08-11
UY38982A (es) 2021-06-30
CA3164528A1 (en) 2021-06-17
EP4072520B1 (en) 2025-09-24
BR112022010574A2 (pt) 2022-08-23
US20230045509A1 (en) 2023-02-09
CN114786648A (zh) 2022-07-22
EP4072520C0 (en) 2025-09-24
JP2023505543A (ja) 2023-02-09

Similar Documents

Publication Publication Date Title
MX2022006940A (es) Composiciones farmaceuticas.
DOP2021000195A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
TR201909152T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı.
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
CR20210664A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
AR120655A1 (es) Anticuerpos ampliamente neutralizantes contra vih
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
MX388699B (es) Formas cristalinas de cabotegravir de sodio
AR122350A1 (es) Composiciones farmacéuticas
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek
BR112016026814A8 (pt) 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica